학술논문
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
Document Type
Article
Author
Voss, Martin H; Gurney, Howard; Atduev, Vagif; Suárez, Cristina; Climent, Miguel Ángel; Pook, David William; Tomczak, Piotr; Barthelemy, Philippe; Lee, Jae-Lyun; Nalbandian, Taron; Stus, Viktor; Ferguson, Thomas; Wiechno, Pawel; Gokmen, Erhan; Lacombe, Louis; Gedye, Craig; Burgents, Joseph E.; Sharma, Manish; Cornell, Jerry; Albiges, Laurence
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p2-2, 5p
Subject
Language
ISSN
0732183X